Key result
Having HF% < 20% and LF:HF ratio > 1.3 at 1317 m was associated with increased odds of developing acute mountain sickness at 3440 m (OR 7.00; 95% CI 1.11-44.06; P=0.047).
Why the study?
Do spectral components of heart rate variability at lower altitude predict acute mountain sickness at high altitude in trekkers?
Cohort (n=32)
Do spectral components of heart rate variability at lower altitude predict acute mountain sickness at high altitude in trekkers?
Odds Ratio: 7 (95% CI 1.11–44.06)
p-value: p=0.047
Heart rate variability parameters (HF% < 20% and LF:HF ratio > 1.3) measured at lower altitudes may serve as important predictors for the development of acute mountain sickness at higher altitudes.
HRV at lower altitude may predict AMS in trekkers; leaves open prospective validation before guiding altitude prophylaxis.
OBJECTIVE: To determine the change and relationship of spectral components of heart rate variability (HRV) measurements in subjects with or without acute mountain sickness (AMS) at both low and high altitude. DESIGN: A prospective study. SETTING: A 12-day itinerary by trekking to the Namche Bazaar, 3440 m in Nepal. PARTICIPANTS: A total of 32 subjects were recruited. INTERVENTIONS: The alternations were measured by heart rate (HR), arterial oxygen saturation (SpO(2)), and spectral analysis of HRV at sea level, 1317 m, 3440 m, 1317 m, and sea level, respectively. MAIN OUTCOME MEASURES: Spectral analysis of HRV. RESULTS: There were statistically significant increases in HR and decreases in SpO(2) in all subjects at high altitude. In HRV, the values of R-R interval, total variance, high frequency (HF), low frequency (LF), and HF% were significantly lower at 3440 m than at sea level, respectively (P < 0.05). The subjects with AMS had significantly lower total variance, HF, and HF%, respectively, but higher LF:HF ratio (P < 0.05) at 3440 m. Subjects with both HF% < 20% (nu) and LF:HF ratio > 1.3 measured at 1317 m had odds ratios of 7.00 (95% confidence interval, 1.11 to 44.06; P = 0.047) to get AMS at 3440 m. CONCLUSIONS: The HRV measurements in total variances, HF, and HF% in trekkers with AMS were statistically significantly lower at high altitude. HF% < 20% (nu) or LF:HF ratio > 1.3 at lower altitudes could be an important predication parameter of trekkers with AMS at higher altitudes.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2010) conducted a cohort in Acute mountain sickness (n=32). HF% < 20% (nu) and LF:HF ratio > 1.3 at 1317 m was evaluated on Acute mountain sickness (AMS) at 3440 m (OR 7.00, 95% CI 1.11 to 44.06, p=0.047). Having HF% < 20% and LF:HF ratio > 1.3 at 1317 m was associated with increased odds of developing acute mountain sickness at 3440 m (OR 7.00; 95% CI 1.11-44.06; P=0.047).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: